Nuvation Bio (NUVB) has quietly turned into one of the market’s stronger biotech movers, with the stock up about 78% over the past month and more than tripling year to date. See our latest analysis ...

Wondering if Nuvation Bio at around 8.66 is still a smart buy after its big run, or if most of the upside is already priced in? This article is designed to unpack that value question in plain English.

Nuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Fintel reports that on December 11, 2025, HC Wainwright & Co. maintained coverage of Nuvation Bio (NYSE:NUVB) with a Buy ...

Live webcasts of each fireside chat will be available on the Investor Relations section of the Nuvation Bio website. An archived recording will be available for 90 days following each event. Nuvation ...

Nuvation Bio (NUVB) shares have caught investor attention following recent trading activity that pushed the stock up more than 50% over the past month. The move has sparked new conversations about the ...

Following these transactions, Liu directly owns 18,000 shares of Nuvation Bio Inc. In other recent news, Nuvation Bio Inc. reported its third-quarter 2025 earnings, significantly surpassing ...

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief ...

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Nuvation Bio is downgraded from Buy to Hold as its stock price now reflects improved Ibtrozi rollout visibility and strong fundamentals. Ibtrozi's commercial launch is robust, with early patient ...

Nuvation Bio Inc (NUVB) reached a significant milestone as its stock hit a 52-week high of $8.09, a dramatic climb from its 52-week low of $1.54. This achievement underscores a remarkable year for the ...

Investing.com - Nuvation Bio Inc (NYSE:NUVB) received a Buy rating initiation from B.Riley on Wednesday, with analyst Mayank Mamtani setting a $12.00 price target for the biopharmaceutical company.